PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Diabetes, Obesity and Metabolism10.1111/dom.146402022Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetesChristophe E. M. De Block, Eveline Dirinck, Ann Verhaegen, Luc F. Van Gaalhttps://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14640, https://onlinelibrary.wiley.com/doi/full-xml/10.1111/dom.14640, https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14640
Diabetes Spectrum10.2337/ds16-00262017303202-210Glucagon-Like Peptide 1 Receptor Agonists for Type 2 DiabetesDeborah Hinnenhttps://diabetesjournals.org/spectrum/article-pdf/30/3/202/505130/202.pdf, https://diabetesjournals.org/spectrum/article-pdf/30/3/202/505130/202.pdf
Handbook of Incretin-based Therapies in Type 2 Diabetes10.1007/978-3-319-08982-9_3201631-43Glucagon-like peptide-1 receptor agonistsBaptist Gallwitzhttp://link.springer.com/content/pdf/10.1007/978-3-319-08982-9_3
Annals of Pediatric Endocrinology & Metabolism10.6065/apem.2017.22.1.15201722115Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetesSeungah Lee, Dong Yun Leehttps://synapse.koreamed.org/pdf/10.6065/apem.2017.22.1.15, https://synapse.koreamed.org/DOIx.php?id=10.6065/apem.2017.22.1.15, http://e-apem.org/upload/pdf/apem-22-15.pdf
Clinical Therapeutics10.1016/j.clinthera.2017.03.01320173961244-1264Treatment Strategy for Type 2 Diabetes with Obesity: Focus on Glucagon-like Peptide-1 Receptor AgonistsQiuhe Jihttps://api.elsevier.com/content/article/PII:S0149291817301959?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S0149291817301959?httpAccept=text/plain
Canadian Journal of Diabetes10.1016/j.jcjd.2017.02.0032017WITHDRAWN: Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 DiabetesJulie A. Lovshinhttps://api.elsevier.com/content/article/PII:S1499267116305329?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1499267116305329?httpAccept=text/plain
Journal of Diabetes Investigation10.1111/jdi.129112018102196-201Glucagon-like peptide-1 receptor agonists for type 2 diabetes: A rational drug developmentBo Ahrénhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fjdi.12911, http://onlinelibrary.wiley.com/wol1/doi/10.1111/jdi.12911/fullpdf
Diabetes mellitus10.14341/dm88042017204286-298Evolution of glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetesGagik R. Galstyan, Evgeniya A. Karataeva, Ekaterina A. Yudovichhttps://dia-endojournals.ru/dia/article/viewFile/8804/6915, https://dia-endojournals.ru/dia/article/viewFile/8804/6915
Diabetes Care10.2337/dc11-s231201134Supplement_2S279-S284Long-Acting Glucagon-Like Peptide 1 Receptor AgonistsAlan J. Garberhttps://diabetesjournals.org/care/article-pdf/34/Supplement_2/S279/609257/s279.pdf, https://diabetesjournals.org/care/article-pdf/34/Supplement_2/S279/609257/s279.pdf
The Journal of Korean Diabetes10.4093/jkd.2018.19.1.35201819135Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes AssociationHyun Jin Kimhttps://synapse.koreamed.org/pdf/10.4093/jkd.2018.19.1.35, https://synapse.koreamed.org/DOIx.php?id=10.4093/jkd.2018.19.1.35, https://e-jkd.org/DOIx.php?id=10.4093/jkd.2018.19.1.35